Radius Health to Announce Third Quarter 2017 Financial Results, Host Conference Call and Live Webcast on November 2, 2017
October 09 2017 - 9:00AM
Radius Health (Nasdaq:RDUS) announced today that it will release
its third quarter 2017 financial results on Thursday, November 2,
2017. The Company will host a conference call and live audio
webcast at 4:30 p.m. ET that day to discuss the results and provide
a company update.
Conference Call
Information:Date: Thursday, November 2,
2017Time: 4:30 p.m. ETDomestic Dial-in
Number: (866) 323-7965International Dial-in
Number: (346) 406-0961Conference ID:
96777747Live webcast:
https://edge.media-server.com/m6/p/5c3izimp
A replay of the conference call/webcast will be available from
November 2, 2017 at 7:30 p.m. ET until November 9, 2017 at 6:30
p.m. ET. To access the replay, dial (855) 859-2056 for U.S. or
(404) 537-3406 for International. The replay conference ID is
96777747.
The live audio webcast of the call can be accessed from the
Investors section of the Company's
website, www.radiuspharm.com. A webcast replay will be also
available for 14 days. The full text of the announcement and
financial results will also be available on the Company's
website.
About RadiusRadius is a science-driven fully
integrated biopharmaceutical company developing and commercializing
innovative therapeutics in the areas of osteoporosis, oncology and
endocrine diseases. Radius' lead product, TYMLOS™ (abaloparatide)
injection, was approved by the U.S. Food and Drug Administration
for the treatment of postmenopausal women with osteoporosis at high
risk for fracture. Radius' Marketing Authorisation Application
(MAA) for abaloparatide-SC for the treatment of postmenopausal
women with osteoporosis is under regulatory review in Europe.
Radius’ clinical pipeline includes an investigational abaloparatide
transdermal patch for potential use in osteoporosis; the
investigational drug elacestrant (RAD1901) for potential use in
hormone-driven and/or hormone-resistant breast cancer, and
vasomotor symptoms in postmenopausal women; and, RAD140, a
non-steroidal, selective androgen receptor modulator (SARM), under
investigation for potential use in hormone receptor positive breast
cancer. For more information, please visit
www.radiuspharm.com.
Investor / Media Relations Contact:Alex
FudukidisTel: (646) 942-5632Email:
alex.fudukidis@russopartnersllc.com
Radius Recycling (NASDAQ:RDUS)
Historical Stock Chart
From Apr 2024 to May 2024
Radius Recycling (NASDAQ:RDUS)
Historical Stock Chart
From May 2023 to May 2024